Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Arthritis Rheum. 2008 Nov;58(11):3485–3497. doi: 10.1002/art.23954

Figure 3.

Figure 3

Bone turnover with GC excess (days 1−56) and after treatments with PTH (1-34) or risedronate at days 29−56. GC excess increased osteoclast formation (TRAP5b) and activity (CTX-I) while it decreased osteoblastic function (osteocalcin). At day 56, PTH (1-34) increased CTX-I and osteocalcin while risedronate decreased both as compared to the GC alone group. *= p < 0.05 from placebo; #= p < 0.05 from GC.